A randomized double-blind study to determine the effect of GK activator (2) [RO 4389620] on efficacy (HbA1c), safety, tolerability and pharmacokinetics in patients with type 2 diabetes mellitus treated with a stable dose of metformin.

Trial Profile

A randomized double-blind study to determine the effect of GK activator (2) [RO 4389620] on efficacy (HbA1c), safety, tolerability and pharmacokinetics in patients with type 2 diabetes mellitus treated with a stable dose of metformin.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Mar 2016

At a glance

  • Drugs Piragliatin (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Sep 2007 Status changed from in progress to completed.
    • 20 Oct 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top